Sol-Gel Technologies (SLGL) EBT Margin (2018 - 2026)
Sol-Gel Technologies (SLGL) reported EBT Margin of 3569.44% for Q1 2026, up 268981.0% year-over-year from N/an in Q1 2025, and up 828.33% quarter-over-quarter from 490.09% in Q4 2025.
Sol-Gel Technologies (SLGL) EBT Margin (2018 - 2026) Analysis & Trends
Sol-Gel Technologies (SLGL) has 9 years of EBT Margin data on file, last reported at 3569.44% in Q1 2026.
- EBT Margin for Q1 2026 came in at 3569.44%, up 268981.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 29.17% (down 195.0% YoY), and the FY2025 annual result was 38.88%, up 6525.0% from the prior year.
- EBT Margin advanced to 3569.44% in Q1 2026 per SLGL's latest filing, from 490.09% in the prior quarter.
- Over five years, EBT Margin peaked at 3569.44% in Q1 2026 and troughed at 6205.0% in Q4 2022.
- A 5-year average of 838.49% and a median of 490.09% in 2025 frame the typical range for EBT Margin.
- The sharpest annual moves came in 2022 and 2023: EBT Margin sank 627208 bps in 2022, then surged 499538 bps in 2023.
- A 5-year view of EBT Margin shows it stood at 6205.0% in 2022, then surged by 81 bps to 1209.62% in 2023, then plunged by 81 bps to 2193.88% in 2024, then soared by 78 bps to 490.09% in 2025, then surged by 828 bps to 3569.44% in 2026.
- Business Quant data shows SLGL's EBT Margin at 3569.44% in Q1 2026, 490.09% in Q4 2025, and 1572.0% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 6.40% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 41.95% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Sol-Gel Technologies | 207.80 Mn | 197.67 Mn | - | 3,569.44% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3,569.44% |
| Dec 31, 2025 | -490.09% |
| Sep 30, 2025 | -1,572.00% |
| Jun 30, 2025 | 65.06% |
| Mar 31, 2025 | 879.63% |
| Dec 31, 2024 | -2,193.88% |
| Sep 30, 2024 | -15.44% |
| Jun 30, 2024 | 29.89% |
| Dec 31, 2023 | -1,209.62% |
| Sep 30, 2023 | -2,961.03% |
| Jun 30, 2023 | -1,098.82% |
| Dec 31, 2022 | -6,205.00% |
| Sep 30, 2022 | -1,388.89% |
| Jun 30, 2022 | 13.16% |
| Mar 31, 2022 | 0.20% |
| Dec 31, 2021 | 67.08% |
| Sep 30, 2021 | 95.21% |
| Jun 30, 2021 | 866.59% |
| Mar 31, 2021 | 602.57% |
| Dec 31, 2020 | -324.99% |